Comparison of the diagnostic sensitivity of SARS-CoV-2 nucleoprotein and glycoprotein-based antibody tests
Detection Principle
ImmunoAssay-Antibody
Target
IgG (Abbott, Novatec, Virotech, Euroimmun and Mediagnost); Variuos Ab (ECLIA from Roche and the MIA from Siemens); Ab vs N (Abbott, Roche, Novatec and Virotech); Ab vs S1, RBD (Siemens, Euroimmun and Mediagnost);
Testing Method Category
Mixed
Testing Method - Additional Info
Roche Elecsys Anti-SARS-CoV-2, Abbott Architect SARS-CoV-2 IgG, Novatec Novalisa SARS-CoV-2 IgG ELISA, Virotech SARS-CoV-2 IgG ELISA, Euroimmun Anti-SARS-CoV-2-ELISA (IgG), Mediagnost Anti-SARS CoV-2 ELISA, and Siemens Atellica IM COV2T.
Reported Performance
Sensitivity: 80% (Roche, 2-3 weeks), 80% (Abbott, 2-3 weeks), 72% (Novatec, 2-3 weeks), 64% (Virotech, 2-3 weeks), 80%(Siemens, 2-3 weeks), 72% (Euroimmun, 2-3 weeks), 52% (Mediagnost, 2-3 weeks), 95.8% (Roche, >4weeks), 83.3% (Abbott, >4 weeks), 66.7% (Novatec, >4 weeks), 66.7% (Virotech, >4 weeks), 100% (Siemens, >4 weeks), 89.6% (Euroimmun, >4 weeks), 70.8% (Mediagnost, >4 weeks), 90.4% (Roche, overall), 82.2% (Abbott, overall), 68.5% (Novatec, overall), 65.8% (Virotech, overall), 93.2% (Siemens, overall), 83.6% (Euroimmun, overall), 64.4% (Mediagnost, overall)
The database contains available information from scientific literature that is being updated periodically. Please note that the provided information (as retrieved from analysed papers) is provided only for devices commercially available with CE-IVD mark. Acknowledgements
